Search Results - "Maschio, Michael"

The potential public health and economic value of a hypothetical COVID-19 vaccine in the United States: Use of cost-effectiveness modeling to inform vaccination prioritization by Kohli, Michele, Maschio, Michael, Becker, Debbie, Weinstein, Milton C.

“…Researchers are working at unprecedented speed to develop a SARS-CoV-2 vaccine. We aimed to assess the value of a hypothetical vaccine and its potential public…”
Get full text

Substantial reduction in the clinical and economic burden of disease following variant-adapted mRNA COVID-19 vaccines in immunocompromised patients in France by Lee, Amy, Davido, Benjamin, Beck, Ekkehard, Demont, Clarisse, Joshi, Keya, Kohli, Michele, Maschio, Michael, Uhart, Mathieu, El Mouaddin, Nadia

“…An evaluation was conducted to predict the economic and clinical burden of vaccinating all immunocompromised (IC) individuals aged ≥30 years with mRNA-1273…”
Get full text

The cost-effectiveness of an adjuvanted quadrivalent influenza vaccine in the United Kingdom by Kohli, Michele A., Maschio, Michael, Mould-Quevedo, Joaquin F., Drummond, Michael, Weinstein, Milton C.

“…In the United Kingdom (UK), both the MF59-adjuvanted quadrivalent influenza vaccine (aQIV) and the high-dose QIV (QIV-HD) are preferred for persons aged…”
Get full text

Cost-effectiveness of high-dose versus standard-dose inactivated influenza vaccine in adults aged 65 years and older: an economic evaluation of data from a randomised controlled trial by Chit, Ayman, Dr, Becker, Debbie L, MSc, DiazGranados, Carlos A, MD, Maschio, Michael, MSc, Yau, Eddy, PhD, Drummond, Michael, Prof

“…Summary Background Adults aged 65 years and older account for most seasonal influenza-related hospital admissions and deaths. Findings from the randomised…”
Get full text

The Cost-Effectiveness of Vaccination of Older Adults with an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Other Available Quadrivalent Vaccines in Germany by Kohli, Michele A., Maschio, Michael, Cartier, Shannon, Mould-Quevedo, Joaquin, Fricke, Frank-Ulrich

“…Enhanced quadrivalent influenza vaccines that include an adjuvant (aQIV) or a high dose of antigen (QIV-HD), which stimulate a stronger immune response in…”
Get full text

The Potential Economic Impact of the Updated COVID-19 mRNA Fall 2023 Vaccines in Japan by Fust, Kelly, Joshi, Keya, Beck, Ekkehard, Maschio, Michael, Kohli, Michele, Lee, Amy, Hagiwara, Yuriko, Van de Velde, Nicolas, Igarashi, Ataru

“…This analysis estimates the economic and clinical impact of a Moderna updated COVID-19 mRNA Fall 2023 vaccine for adults ≥18 years in Japan. A previously…”
Get full text

Despite High Cost, Improved Pneumococcal Vaccine Expected To Return 10-Year Net Savings Of $12 Billion by Kohli, Michele A, Farkouh, Raymond A, Maschio, Michael J, McGarry, Lisa J, Strutton, David R, Weinstein, Milton C

“…In 2010 the US Advisory Committee on Immunization Practices recommended that the seven-valent pneumococcal conjugate vaccine (PCV7) be replaced by the…”
Get full text

The Cost-Effectiveness of Expanding Vaccination with a Cell-Based Influenza Vaccine to Low Risk Adults Aged 50 to 64 Years in the United Kingdom by Kohli, Michele A., Maschio, Michael, Mould-Quevedo, Joaquin F., Ashraf, Mansoor, Drummond, Michael F., Weinstein, Milton C.

“…Background: In response to COVID-19, the UK National Health Service (NHS) extended influenza vaccination in 50- to 64-year-olds from at-risk only to all in…”
Get full text

An Economic Comparison of Influenza Vaccines Recommended for Use in Eligible Adults under 65 Years in the United Kingdom by Maschio, Michael, Kohli, Michele A, Ashraf, Mansoor, Drummond, Michael F, Weinstein, Milton C, Mould-Quevedo, Joaquin F

“…: In the United Kingdom (UK), a cell-based quadrivalent influenza vaccine (QIVc) and a recombinant vaccine (QIVr) are recommended for eligible adults under 65…”
Get full text

Projections of the incidence of COVID-19 in Japan and the potential impact of a Fall 2023 COVID-19 vaccine by Kohli, Michele, Maschio, Michael, Lee, Amy, Igarashi, Ataru

“…•Estimates incidence of COVID-19 infection, hospitalization, & deaths in Japan.•Examines potential impact of Fall 2023 COVID-19 vaccine on clinical…”
Get full text

Clinical impact and cost-effectiveness of the updated COVID-19 mRNA Autumn 2023 vaccines in Germany by Joshi, Keya, Scholz, Stefan, Maschio, Michael, Kohli, Michele, Lee, Amy, Fust, Kelly, Ultsch, Bernhard, Van de Velde, Nicolas, Beck, Ekkehard

“…To assess the potential clinical impact and cost-effectiveness of coronavirus disease 2019 (COVID-19) mRNA vaccines updated for Autumn 2023 in adults aged ≥60…”
Get more information

A Budget Impact Model of the Addition of Telotristat Ethyl Treatment to the Standard of Care in Patients with Uncontrolled Carcinoid Syndrome by Fust, Kelly, Maschio, Michael, Kohli, Michele, Singh, Simron, Pritchard, D. Mark, Marteau, Florence, Myrenfors, Peter, Feuilly, Marion

“…Background Carcinoid syndrome, a rare condition in patients with neuroendocrine tumours, characterised by flushing and diarrhoea, severely affects patients’…”
Get full text

The potential clinical impact and cost-effectiveness of the updated COVID-19 mRNA fall 2023 vaccines in the United States by Kohli, Michele A, Maschio, Michael, Joshi, Keya, Lee, Amy, Fust, Kelly, Beck, Ekkehard, Van de Velde, Nicolas, Weinstein, Milton C

“…To assess the potential clinical impact and cost-effectiveness of COVID-19 mRNA vaccines updated for fall 2023 in adults aged ≥18 years over a 1-year analytic…”
Get more information

Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma by Fust, Kelly, Li, Xiaoyan, Maschio, Michael, Villa, Guillermo, Parthan, Anju, Barron, Richard, Weinstein, Milton C., Somers, Luc, Hoefkens, Caroline, Lyman, Gary H.

“…Objective The objective of this study was to evaluate the cost effectiveness of no prophylaxis, primary prophylaxis (PP), or secondary prophylaxis (SP) with…”
Get full text

High-dose inactivated influenza vaccine is associated with cost savings and better outcomes compared to standard-dose inactivated influenza vaccine in Canadian seniors by Becker, Debbie L., Chit, Ayman, DiazGranados, Carlos A., Maschio, Michael, Yau, Eddy, Drummond, Michael

“…Seasonal influenza infects approximately 10-20% of Canadians each year, causing an estimated 12,200 hospitalizations and 3,500 deaths annually, mostly…”
Get full text

A Better Life by MASCHIO, MICHAEL

“…A short story is presented…”
Get full text

Cost-effectiveness of prophylaxis treatment strategies for febrile neutropenia in patients with recurrent ovarian cancer by Fust, Kelly, Li, Xiaoyan, Maschio, Michael, Barron, Richard, Weinstein, Milton C, Parthan, Anju, Walli-Attaei, Marjan, Chandler, David B, Lyman, Gary H

“…Abstract Objective Evaluate the cost-effectiveness of primary prophylaxis (PP) or secondary prophylaxis (SP) with pegfilgrastim, filgrastim (6-day and 11-day),…”
Get full text

Granulocyte colony-stimulating factors in the prevention of febrile neutropenia: review of cost-effectiveness models by Fust, Kelly, Parthan, Anju, Maschio, Michael, Gu, Qing, Li, Xiaoyan, Lyman, Gary H, Tzivelekis, Spiros, Villa, Guillermo, Weinstein, Milton C

“…We reviewed the evolution of the methods used in cost-effectiveness analyses of granulocyte colony-stimulating factors (G-CSFs) in the primary and secondary…”
Get more information

Economic analysis of bevacizumab, cetuximab, and panitumumab with fluoropyrimidine-based chemotherapy in the first-line treatment of KRAS wild-type metastatic colorectal cancer (mCRC) by Lawrence, Donna, Maschio, Michael, Leahy, Kevin J, Yunger, Simon, Easaw, Jacob C, Weinstein, Milton C

“…Colorectal cancer (CRC) is the third most commonly diagnosed cancer in Canada (excluding non-melanoma skin cancers). Bevacizumab is a recombinant humanized…”
Get more information

Lifetime cost-effectiveness of prophylactic implantation of a cardioverter defibrillator in patients with reduced left ventricular systolic function: results of Markov modelling in a European population by Cowie, Martin R., Marshall, Deborah, Drummond, Michael, Ferko, Nicole, Maschio, Michael, Ekman, Matthias, de Roy, Luc, Heidbuchel, Hein, Verboven, Yves, Braunschweig, Frieder, Linde, Cecilia, Boriani, Giuseppe

“…Aims Current European guidelines recommend prophylactic implantation of cardioverter defibrillators (ICDs) in patients with a reduced left ventricular ejection…”
Get full text